The SELDI-TOF MS Approach to Proteomics: Protein Profiling and Biomarker Identification

doi:10.1006/bbrc.2002.6678

Biochemical and Biophysical Research Communications

Volume 292, Issue 3, 5 April 2002, Pages 587-592

https://doi.org/10.1006/bbrc.2002.6678 Get rights and content

Abstract

The need for methods to identify disease biomarkers is underscored by the survival-rate of patients diagnosed at early stages of cancer progression. Surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) is a novel approach to biomarker discovery that combines two powerful techniques: chromatography and mass spectrometry. One of the key features of SELDI-TOF MS is its ability to provide a rapid protein expression profile from a variety of biological and clinical samples. It has been used for biomarker identification as well as the study of protein–protein, and protein–DNA interaction. The versatility of SELDI-TOF MS has allowed its use in projects ranging from the identification of potential diagnostic markers for prostate, bladder, breast, and ovarian cancers and Alzheimer's disease, to the study of biomolecular interactions and the characterization of posttranslational modifications. In this minireview we discuss the application of SELDI-TOF MS to protein biomarker discovery and profiling.

References (21)

G.E. Stoica et al.
Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin
J. Biol. Chem.
(2001)
J. Hinshelwood et al.
Identification of the C3b binding site in a recombinant vWF-A domain of complement factor B by surface enhanced laser desorption–ionization affinity mass spectrometry and homology modeling: Implications for the activity of Factor B
J. Mol. Biol.
(1999)
A. Chernyak et al.
Conjugating oligosaccharides to proteins by squaric acid diester chemistry: Rapid monitoring of the progress of conjugation, and recovery of the unused ligand
Carbohydrate Res.
(2001)
C.E. Forde et al.
A rapid method to capture and screen for transcription factors by SELDI mass spectrometry
Biochem. Biophys. Res. Commun.
(2002)
K. Sato et al.
Mass spectrometric high-throughput analysis of serum-free conditioned medium from cancer cell lines
Cancer Lett.
(2001)
T.W. Hutchens et al.
New desorption strategies for the mass spectrometric analysis of macromolecules
Rapid. Commun. Mass Spectrom.
(1993)
M. Merchant et al.
Recent advancements in surface enhanced laser desorption/ionization time of flight mass spectrometry
Electrophoresis
(2000)
V.F. Eggeling et al.
Mass spectrometry meets chip technology: A new proteomic tool in cancer research
Electrophoresis
(2001)
P.R. Srinivas et al.
Proteomics in early detection of cancer
Clin. Chem.
(2001)
C.P. Paweletz et al.
New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics
Urology
(2001)

There are more references available in the full text version of this article.

Cited by (503)

Alternative biological screening methods
2023, Computational Approaches in Drug Discovery, Development and Systems Pharmacology
The emergence and re-emergence of life-threatening infectious diseases and health ailments demand newer drug screening strategies. Novel drug discovery and screening strategies require comprehensive knowledge of the underlying molecular mechanisms that partake in disease metabolism and regulation and in-depth insight into the genomes of disease-causing microbes. For this, representative disease models are needed along with the advanced and integrated biological and computational screening approaches to accelerate the drug discovery process. In the past few decades, efforts have been made to boost the process of novel drug discovery for clinical application with no significant success in the field. In this chapter, several aspects of available biological screening methodologies have been discussed in detail along with their advantages and limitations. Meticulous selection and implementation of these methodologies and approaches either individually or in combination have the potential to boost the process of drug discovery and development.
Applications of proteomics in cancer diagnosis
2023, Proteomics: A Promising Approach for Cancer Research
Scientists and health persons face a significant challenge in detecting cancers in their early stages, when there appears to be a greater chance of treatment, because most diagnostic blood biomarker detection methods lack sufficient specificity and sensitivity. Numerous treatment approaches for benign and invasive cancers have been inspired by advancements in health care technology and a committed focus from the scientific community. While these advancements frequently lead to better prognosis and longer patient lives, methods for early diagnosis and severity stratification have lagged. Despite the fact that the exact causes of most tumors are unknown, cancer is thought to be caused by a combined effect of environmental and genetic flaws. Mutations, chromosomal abbreviations, copy-number variations, alternative splicing, and other factors have all been identified as contributing factors. The current understanding of cancer diversity and biospecimen variability is one of the important and difficult aspects of using proteomics and other omics technologies in cancer research. In cancer patients, combining panels of various circulating biomarkers, rather than a single molecule, with new advanced or modified techniques such as imaging tests/procedures may be more helpful in early assessment/diagnosis, accurate prognosis, and treatment response. Proteomic technologies now have evolved as an important complement to genomic as well as antibody-based diagnosis technologies. Proteomic technologies may aid in the development of molecular diagnostics and cancer markers for early detection. However, in order to obtain the best information for a patient’s clinical care, data from multiple diagnostic technologies must be combined. Proteins are separated on 2D (two dimensional) gels and visualized spots are identified in traditional proteomics methods. Proteins are then identified using Western blot and fluorescence methods. Mass spectrometry and MALDI.MS (Matrix-Assisted Laser Desorption Mass Spectrometry is then used to analyze and characterize the proteins. An overall view of the latest applications that allow for the rapid identification of promising biomarkers and therapeutic targets in breast, ovarian, lung, prostate, colorectal, esophageal, leukemia, and pancreatic cancer.
Exploring the macromolecules for secretory pathway in cancer disease
2023, Advances in Protein Chemistry and Structural Biology
Secretory proteins play an important role in the tumor microenvironment and are widely distributed throughout tumor tissues. Tumor cells secrete a protein that mediates communication between tumor cells and stromal cells, thereby controlling tumor growth and affecting the success of cancer treatments in the clinic. The cancer secretome is produced by various secretory pathways and has a wide range of applications in oncoproteomics. Secretory proteins are involved in cancer development and tumor cell migration, and thus serve as biomarkers or effective therapeutic targets for a variety of cancers. Several proteomic strategies have recently been used for the analysis of cancer secretomes in order to gain a better understanding and elaborate interpretation. For instance, the development of exosome proteomics, degradomics, and tumor-host cell interaction provide clear information regarding the mechanism of cancer pathobiology. In this chapter, we emphasize the recent advances in secretory protein and the challenges in the field of secretome analysis and their clinical applications.
Fast screening of short-chain chlorinated paraffins in indoor dust samples by graphene-assisted laser desorption/ionization mass spectrometry
2018, Talanta
Citation Excerpt :
As analytical sensitivity is still a major concern in analysis of SCCPs, such an improvement should be of high value for SCCP studies. Noteworthily, these LODs were achieved by direct MALDI-TOF MS with no sample enrichment, and they may be further lowered by integrating preconcentration procedures in the methodology development (e.g., using a surface-enhanced laser desorption/ionization (SELDI) probe) [46–50]. More importantly, MALDI-TOF MS provides a much faster and higher-throughput method for screening of SCCPs than other techniques.
As an important class of emerging chemical contaminants, short-chain chlorinated paraffins (SCCPs) are considered as one of the most challenging groups of compounds to analyze. In this paper, we report a new method for fast screening of SCCPs based on matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) with graphene as a matrix and 2,5,6,9-tetrachlorodecane as an internal standard. We found that the use of graphene as MALDI matrix generated high peak intensities for SCCPs while producing few background noises. The ion fragmentation mechanisms of SCCPs in MALDI are discussed in detail. Under the optimized conditions, much lower detection limits of SCCP congeners (0.1–5 ng/mL) than those reported previously were obtained. Other distinct advantages such as short analysis time and simplified sample preparation procedures are also demonstrated. The method was successfully applied in fast screening of SCCPs in indoor dust samples and monitoring of human exposure levels to SCCPs, and the results were verified by gas chromatography coupled to negative chemical ionization quadrupole time-of-flight high-resolution mass spectrometry. This work not only offers a new promising tool for SCCP studies, but also further demonstrates the promise of graphene as a new generation of MALDI matrix.
An ultrasensitive micropillar-based quartz crystal microbalance device for real-time measurement of protein immobilization and protein-protein interaction
2018, Biosensors and Bioelectronics
A new sensing device was developed to achieve ultrahigh sensitivity, by coupling polymer micropillars with a quartz crystal microbalance (QCM) substrate to form a two-degree- of-freedom resonance system (QCM-P). The sensitivity of these QCM-P devices was evaluated by measuring mass changes for both deposited gold film and adsorption of bovine serum albumin (BSA), respectively, on poly(methyl methacrylate) (PMMA) micropillar surfaces, as well as assessing ligand-analyte binding interactions between anti-human immunoglobulin G (anti-hIgG) and human immunoglobulin G (hIgG). The anti-hIgG and hIgG binding results show QCM-P achieved an eightfold improvement in sensitivity relative to conventional QCM sensors. In addition, the binding affinity obtained from the QCM-P device for anti-hIgG and hIgG proteins was found in good agreement with that measured by surface plasmon resonance (SPR) for the same binding reaction.
Differential proteome profile in ischemic heart disease: Prognostic value in chronic angina versus myocardial infarction. A proof of concept
2017, Clinica Chimica Acta
The initial clinical manifestation of ischemic heart disease (IHD) i.e. unheralded myocardial infarction (MI) versus chronic angina pectoris (AP) is statistically associated with adverse or mild disease progression respectively in the long-term follow-up. Here, we subjected AP and MI patients to blood proteomic analysis by Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (SELDI-TOF-MS) in order to investigate putative new prognostic biomarkers of IHD manifestation. We found several differentially expressed peaks but four of them (4176, 4475, 14,158 m/z and 8922 m/z for AP and MI, respectively) were most reliable. Two of them were identified; 14,158 m/z peak was the double-charged form of Apolipoprotein A-I and its vasoprotective action accords with prominence in AP. The 4176 m/z peak was related to FAM83C protein, while neither the 4475 m/z peak nor the MI-linked 8922 m/z peak could be identified. We conclude that SELDI-TOF-MS analysis may yield a panel of molecular signals able to retrospectively classify patients according to their clinical and molecular features, exploitable for predicting the natural course of IHD.

View all citing articles on Scopus

¹: To whom correspondence and reprint requests should be addressed at SAIC-Frederick, Inc., National Cancer Institute at Frederick, P.O. Box B, Building 469, Room 155, Frederick, MD 21702. Fax: 301-846-6037. E-mail: [email protected].

View full text

Breakthroughs and ViewsThe SELDI-TOF MS Approach to Proteomics: Protein Profiling and Biomarker Identification

Abstract

J. Biol. Chem.

J. Mol. Biol.

Carbohydrate Res.

Biochem. Biophys. Res. Commun.

Cancer Lett.

New desorption strategies for the mass spectrometric analysis of macromolecules

Rapid. Commun. Mass Spectrom.

Recent advancements in surface enhanced laser desorption/ionization time of flight mass spectrometry

Electrophoresis

Mass spectrometry meets chip technology: A new proteomic tool in cancer research

Electrophoresis

Proteomics in early detection of cancer

Clin. Chem.

New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics

Urology

Breakthroughs and Views
The SELDI-TOF MS Approach to Proteomics: Protein Profiling and Biomarker Identification